Posted on

Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia A patients with inhibitors

General Track – Cycle 2 | Drugs

HTA Council Recommendation (as of 29 April 2025)

The HTA Council recommends the government financing of Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia A patients with inhibitors. (See below for more details)

Relevant Information

  • Dosage Strengths:
    • 500 units/10mL (50 units/mL);
    • 1000 units/20mL (50 units/mL);
    • 2500 units/50mL (50 units/mL)
  • Status: With Final HTA Council Recommendation
  • Topic Assignment: Internal Assessment
  • Policy Question: Should Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia A patients with inhibitors be funded by the government?
  • Secretary of Health Decision: pending

Evidence and Relevant Documents

Back to Assessments Page